P484 Hepatitis B vaccination in inflammatory bowel disease

Pinto, J Cortez; Castela, Joana; Moleiro, Joana; Silva, J Pereira da; Rosa, Isadora; Pereira, A Dias

doi:10.1093/ecco-jcc/jjy222.608

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the full texts, 21 studies were included for the analysis 7,17–36 . Details of excluded studies are provided in Table S2 37–51 . Of the included studies, 17 were full articles 7,17–26,29,31–35 and 4 were published as abstracts 27,28,29,31 .…”

Section: Resultsmentioning

confidence: 99%

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Singh

Jena

Mahajan

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background:The response rate of hepatitis B virus (HBV) vaccination in patients with inflammatory bowel disease (IBD) is variable. Increasing dose or accelerated schedule is the suggested strategy to improve seroconversion. Aim:We performed a meta-analysis to determine the pooled response rate of HBV vaccination and to identify the predictors of seroconversion. Methods:We searched PubMed, Embase and Cochrane library databases. Studies reporting the response of HBV vaccination in IBD patients were included. Response was recorded as adequate immune response (AIR, >10 IU/L) and Effective immune response (EIR, >100 IU/L). Pooled AIR and EIR rates were calculated for different doses (10-20 μg or 40 μg) and schedules (standard: 0, 1 and 6 months or accelerated: 0, 1 and 2 months). Meta-analysis was performed to identify the predictors of response.Results: Twenty-one studies including 2602 patients were eligible. Pooled AIR and EIR rates after HBV vaccination were 62% (95% CI, 55-68) and 42% (95% CI, 37-48), respectively. Pooled AIR and EIR rates for standard and double dose were similar.Pooled AIR and EIR rates were also comparable for different schedules of HBV vaccination. Gender, IBD subtype and disease activity did not affect the response rate.Use of immunosuppression [immunomodulators (RR: 0.73, 95% CI, 0.62-0.87) and anti-TNFs (RR: 0.72, 95% CI, 0.60-0.87)] was a predictor of poor immune response compared to no immunosuppressive therapy. Conclusion:Patients with IBD have a poor serological response after HBV vaccination. HBV screening and vaccination should preferably be done before starting the immunosuppressive drugs.

show abstract